(Hypertension. 1999;33:373-377.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Departments of Physiology (J.R.S., J.M.H., J.L.) and Medicine (B.P.H.), University of Maryland, and Veterans Administration Medical Center (B.P.H.), Baltimore, Md.
Correspondence to Jui R. Shah, PhD, Department of Physiology, School of Medicine, University of Maryland at Baltimore, 655 W Baltimore St, Baltimore, MD 21201. E-mail jshah{at}umaryland.edu
| Abstract |
|---|
|
|
|---|
218 and
232 nmol/L, respectively. Sodium pumpmediated 86Rb
uptake was inhibited by ouabain (EC50
301 nmol/L). Ang
II dose dependently augmented secretions of EO and
aldosterone, increased ouabain-sensitive 86Rb
uptake and 3H-ouabain binding, and increased the affinity
for 3H-ouabain binding (Kd, from
205 to 80 nmol/L) with no change in the maximal number of sodium pumps
(5.45x106) per cell. Losartan blocked all effects
of Ang II except EO secretion, which was inhibited by PD123319. We
conclude that BAG cells express sodium pumps in high density and bind
ouabain to a single class of low-affinity sites. The characteristics of
the sodium pumps protect BAG cells from EO autotoxicity but may exclude
them from mediating feedback inhibition of EO secretion. The effects of
Ang II on sodium pump activity, ouabain binding affinity, and
aldosterone secretion are mediated via Ang II type 1
receptors, whereas Ang II type 2 receptors augment EO secretion. The
role of the Ang IImediated increase in the ouabain sensitivity of BAG
cell sodium pumps in the secretions of aldosterone and EO
remains to be elucidated.
Key Words: cardiac glycosides adrenal Na,K-ATPase secretion cell culture
| Introduction |
|---|
|
|
|---|
1 counterparts to
the cardenolide ouabain.1 2 3 4 5 Endogenous
"ouabain" (EO) is a specific, high-affinity, reversible
inhibitor of sodium pumps.2 3 5 Moreover, the
classic secretagogues, angiotensin (Ang) II and
adrenocorticotropic hormone, raise EO secretion from primary
adrenocortical cultures.6 Previously, we showed that Ang II stimulates aldosterone and EO secretions from bovine adrenal zona glomerulosa (BAG) cells via distinct receptor subtypes.7 Moreover, inhibition of sodium pumps in adrenal cells may augment aldosterone secretion.8 The apparent links between Ang II, EO, sodium pumps, and aldosterone secretion led us to characterize the sodium pump of BAG cells and investigate the effects of Ang II on the pump in concert with measurements of steroid secretion.
| Methods |
|---|
|
|
|---|
4 million (for
secretion experiments) or 1 million (for binding studies) per well. All
experiments were performed with at least triplicate cell cultures.
Steroid Secretion Experiments and Radioimmunoassays
Details are given elsewhere.10 After incubation,
the secretion media was collected and assayed for
aldosterone and EO. They were rinsed with buffer and
dissolved in 1% sodium dodecyl sulfate (SDS) for assay of
total cell protein (BCA) and estimation of cell-associated
radioactivity when appropriate. Aldosterone was measured
with a commercially available radioimmunoassay (RIA) kit
(Diagnostic Products Corp). The RIA has no
cross-reactivity to ouabain or EO. Intra-assay and interassay
coefficients of variation were 6.8% and 8.2%, respectively. EO was
measured by RIA by use of extracted samples and a polyclonal rabbit
antiouabain serum (R8) described elsewhere.11 12 The assay
is highly cross-reactive with EO1 but exhibits no
significant cross-reactivity (<0.01%) with cortisol,
aldosterone, adrenocorticotropic hormone, and Ang II.
Typical intra-assay and interassay coefficients of variation were 6.9%
and 13.6%, respectively.
3H-Ouabain Binding Studies
After removal of the culture medium, the cells were washed twice
with buffer (containing in mmol/L NaCl 145, KCl 5,
CaCl2 2, MgCl2 1, glucose
10, HEPES 10-NaOH, pH 7.4). Buffer containing
3H-ouabain (10 to 300 nmol/L) either alone or
with pharmacological reagents was added to the cells and incubated at
37°C in 5% CO2 for 4 or 8 hours. For
nonspecific binding, 30 µmol/L cold ouabain was present in
the buffer, and specific binding was taken as the difference between
total and nonspecific binding. Competition curves for
3H-ouabain binding were constructed by use of 10
nmol/L 3H-ouabain in the presence of
increasing amounts of cold ouabain. At the end of the experiment, cells
were rinsed with buffer and dissolved in 1% SDS. Total cell protein
(BCA) and cell-associated radioactivity were determined.
86Rb Uptake Studies
The culture medium was removed, and the cells were washed twice
with a secretion buffer containing 2 mmol/L RbCl. Secretion buffer
fortified with 86RbCl (0.11 mmol/L) and
various pharmacological agents was incubated with cells at 37°C in
5% CO2 for 4 hours. The medium was aspirated,
and cells were rinsed 3 times in 2 mL ice-cold buffer with 2
mmol/L RbCl and mixed with 1 mL of 1% SDS for assay of total cell
protein and cell-associated 86Rb (gamma counter).
Pump activity was the difference between uptake in the absence and
presence of 0.1 mmol/L ouabain. Pump fluxes are expressed as
nanomoles of Rb plus potassium per milligram per 4 hours.
Materials
PD123319-ditrifluoroacetate (DTFA) was a gift of Dr David
Taylor (Warner-Lambert, Ann Arbor, Mich). DTFA was removed by
high-performance liquid chromatography before
use. Losartan (DuP 753) was a gift of Dr Ronald Smith (Du Pont
Merck). Collagenase type I and DNase type I were
from Worthington Biochemicals. Percoll was from Pharmacia. Fetal bovine
serum and Dulbecco's modified Eagle's medium were from
GIBCO-BRL. 3H-ouabain was from New England
Nuclear. Other chemicals were from Sigma Chemical Co.
Statistical Analyses
Evaluations of significance were performed with ANOVA and
Fisher's specific test. Results were expressed as mean±SEM, and
P<0.05 was used to indicate significance unless otherwise
noted.
| Results |
|---|
|
|
|---|
7.5-fold rightward when binding was performed in 100 instead of 10
nmol/L 3H-ouabain.
|
To explore the binding affinity of the sodium pumps for cardiac
glycosides, the cells were coincubated with increasing doses of cold
cardiac glycosides in the presence of tracer amounts (10 nmol/L) of
3H-ouabain. As shown in Figure 2
, binding of
3H-ouabain was displaced in a
concentration-dependent manner by both ouabain and digoxin with
IC50 of
218 and
232 nmol/L, respectively.
In each case, the Hill coefficients were nearly unity, indicating the
interaction of ouabain and digoxin with a single class of
3H-ouabain binding sites.
|
Rb+ ions substitute for K+ in stimulating ATP hydrolysis and sodium pumpmediated transport into cells. Preliminary experiments showed that BAG cells accumulated 86Rb and that the ouabain-sensitive component comprised >80% of the uptake over 4 hours (data not shown).
Effects of Ang II Receptors on Ouabain Binding and Sodium Pump
Activity
The effect of Ang II on the binding of
3H-ouabain to BAG cells is shown in Figure 2
. Ang II dose dependently increased the specific binding of
3H-ouabain to BAG cells from a basal of
6 to
>14 fmol/mg at 100 nmol/L Ang II. The EC50 for
Ang II stimulation of 3H-ouabain binding was
1
nmol/L. This value is similar to the EC50 for the
stimulation of corticosteroid secretions,7
suggesting that the same receptor may be involved in both effects.
Further experiments in which the concentration of
3H-ouabain was systematically varied showed that
the effect of Ang II increased the binding of label at all
concentrations tested (Figure 3
).
Moreover, Scatchard analysis (Figure 3
, inset) showed
that the binding of 3H-ouabain to BAG cells under
basal conditions was well fit to a single class of binding sites with
an apparent Kd of 205 nmol/L, and a
Bmax of 35.6 fmol/µg protein. In the
presence of 10 nmol/L Ang II, a single class of binding sites was again
detected whose dissociation constant and maximal binding were 79 nmol/L
and 35.9 fmol/µg, respectively. Thus, Ang II increased the
sensitivity of the sodium pumps to ouabain
3-fold without changing
their number.
|
Figure 4
shows the effects of specific
blockade of Ang II type 1 and 2 receptors on
3H-ouabain binding and sodium pump activity (as
estimated by ouabain-sensitive 86Rb uptake). Ang
II augmented 3H-ouabain binding and increased
sodium pump activity. In parallel incubations, Ang II stimulated
(P<0.05) the secretions of aldosterone (basal,
0.82±0.08 pmol · mg-1 · 2
h-1; Ang II, 5.68±0.57 pmol ·
mg-1 · 2 h-1) and
EO (basal, 0.64±0.04 pmol · mg-1
· 2 h-1; Ang II, 1.5±0.09 pmol ·
mg-1 · 2 h-1).
Except for EO secretion, all effects of Ang II were blocked by
losartan. In contrast, PD123319 specifically inhibited Ang
IIstimulated EO secretion. Neither losartan nor PD123319
affected the measured parameters in the absence of Ang II
(not shown).
|
| Discussion |
|---|
|
|
|---|
Under basal conditions, both the time and concentration dependence of
3H-ouabain binding were pseudolinear (Figure 1
). This is consistent with the use of ligand
concentrations that are significantly less than the receptor affinity.
More than 90% of the total binding was specific. The concentration
dependence of specific binding showed no evidence of saturation even at
300 nmol/L. Changes in potassium ion concentration within the
physiological range reduce the affinity for cardiac
glycoside binding to the sodium pump. The marked potassium ion
sensitivity of the interaction of 3H-ouabain with
BAG cells and the weakened effect of potassium at the highest
concentration of 3H-ouabain used show that
specific binding is mediated exclusively by sodium pumps. Further
analysis of the relationship showed that the competition
between labeled and cold ouabain occurred at a single class of binding
sites whose apparent affinity for ouabain and digoxin was surprisingly
low (Figure 2
). These results, consistent with the
temporal and concentration data in Figure 1
, have other
implications. We suggested previously that feedback inhibition of EO
secretion may be mediated by autoreceptors.6 The
present results suggest that these autoreceptors are not sodium
pumps. For example, the rate of EO secretion falls to
10% of the
initial rate as the concentration of secreted EO rises into the range
of 0.2 to 0.5 nmol/L.6 On the basis of a binding affinity
for ouabain of
200 nmol/L and with equivalent potency assumed, an EO
concentration of 0.5 nmol/L would bind and inhibit
0.25% of the bulk
sodium pumps. Another possibility is that a small number of specialized
pumps are involved. In some cell types, small numbers of sodium pumps
with high ouabain affinity are clustered in functional microdomains
over portions of the sarcoplasmic reticulum. In vascular smooth muscle
cells, nanomolar concentrations of ouabain interact specifically with
these pumps to affect stored calcium, while leaving other sodium pumps
involved in the control of bulk cytosolic sodium
unaffected.20 If such specialized sodium pumps or other
types of ouabain receptors were present in BAG cells, they would
comprise <5% of the specific binding sites measured and would escape
detection by our methods.
Another factor of relevance to BAG cell function is the high density
(5.45x106) of sodium pumps per cell estimated
from Scatchard analysis (Figure 3
). This is reminiscent of tissues such as
nerve, heart, and kidney in which the high copy number typically is
associated with large inward sodium fluxes and high rates of aerobic
metabolism. Moreover, it is consistent with other
reports that have noted high Na,K-ATPase activity in glomerulosa
tissue.8 21
What is the possible significance of high pump turnover, low affinity,
and high pump densities? In other systems in which a ligand may be
present continuously, rapid receptor turnover can serve as a means
to alter signaling. The concentration of EO leaving the dog adrenal is
0.75 nmol/L, roughly 4- to 5-fold higher than that entering the
gland.12 Moreover, the local intra-adrenal concentrations
of EO, in the vicinity of the secretory cells especially during Ang II
stimulation, may be 10-fold higher than those measured in the mixed
venous effluent. Even under these conditions, our calculations suggest
that
12% to 15% of the available pumps could be occupied by EO.
This level of pump blockade would be expected to cause
physiologically relevant increases in cell
sodium and stored calcium that would augment signaling by Ang II and
other stimulants without toxicity. The affinity of the adrenocortical
sodium pump for cardiac glycosides in cows, coupled with a high pump
density, is poised for physiological regulation by
EO while forestalling the potential for autotoxicity in the
adrenocortical environment.
Previous reports of the effects of Ang II on sodium pump activity in
adrenocortical cells are varied. In rat glomerulosa cells and bovine
adrenal cells, Ang II was thought to inhibit sodium
pumps.8 16 Exposure of cells to Ang II does not appear to
affect the Na,K-ATPase activity in isolated
membranes.21 22 Consistent with this impression,
our results showed that Ang II, via Ang II type 1 receptors, increased
both the affinity of BAG sodium pumps for ouabain and their transport
activity (Figure 4
) without upregulation or downregulation of
surface membrane pump number (Figure 3
). The increase in pump
activity in response to Ang II probably originates from an increase in
cell sodium,23 which is known to enhance the formation of
a phosphorylated intermediate of the pump1
whose affinity for ouabain is heightened
simultaneously.
The increased EO secretion occurring at a time when the ouabain
affinity of the BAG cell sodium pump is increased, along with the
demand for heightened active transport, seems paradoxical (Figures 3
and 4
). One possibility is that intra-adrenal EO might
augment Ang IIstimulated aldosterone secretion. In rat
adrenal cells, aldosterone secretion was increased during
inhibition of sodium pumps by both Ang II and ouabain.8 In
other species, some studies reported inhibition,13 14 15 17
stimulation,24 or transient stimulation followed by
inhibition17 18 of aldosterone secretion in
response to ouabain. Studies that observed inhibition of
aldosterone secretion have in general used pharmacological
concentrations of ouabain that would inhibit >50% of the available
sodium pumps. These conditions are often lethal because the activity of
the residual pumps cannot increase sufficiently to normalize outward
sodium flux and cell potassium.
Two recent sets of observations suggest that aldosterone
secretion can be augmented by concentrations of ouabain that could
inhibit no more than a small portion of the bulk sodium pumps. In the
rat, continuous infusions of ouabain for 5 weeks resulted in
circulating plasma levels ranging from
1 to 5 nmol/L. Under these
conditions, plasma aldosterone was dose dependently
elevated, whereas plasma renin activity was unchanged.19
Thus, low concentrations of ouabain approaching the
physiological range of EO provide a strong in vivo
stimulus to aldosterone secretion in the rat. A similar
result, albeit with pharmacological concentrations of ouabain, has been
observed with rat BAG cells in vitro.25 In addition,
Tamura et al26 have shown that ouabain at 10 nmol/L
increased basal aldosterone secretion 2- to 3-fold from
bovine adrenocortical cells in culture and enhanced Ang IIstimulated
secretion. Assuming that their cells exhibited sodium pumps whose
characteristics were similar to those we observed, our calculations
suggest that the binding of ouabain to
15% of the available sodium
pumps is sufficient to augment aldosterone secretion
significantly.
Elevated circulating levels of EO and aldosterone have been
described in
50% of hypertensive patients with surgically confirmed
Conn's syndrome.27 These observations, along with those
mentioned above and the accumulating evidence that the secretions of EO
and aldosterone are regulated differently,7 10
raise the possibility that the hyperaldosteronism in some patients with
Conn's syndrome may be secondary to a primary overproduction
of EO. New classes of agents that block ouabain and EO binding may
distinguish among these patients.28
| Acknowledgments |
|---|
| Footnotes |
|---|
Received September 18, 1998; first decision October 19, 1998; accepted November 6, 1998.
| References |
|---|
|
|
|---|
2.
Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris
DW, Mandel F, Mathews WR, Ludens JH. Identification and
characterization of a ouabain-like compound from human plasma.
Proc Natl Acad Sci U S A. 1991;88:62596263.
3. Schoner W, Heidrich-Lorsbach E, Kirch U, Ahlemeyer B, Sich B. Purification and properties of endogenous ouabain-like substances from hemofiltrate and adrenal glands. J Cardiovasc Pharmacol. 1993;22:S29S31.
4.
Shaikh IM, Lau BWC, Siegfried BA, Valdes R. Isolation
of digoxin-like immunoreactive factors from mammalian adrenal cortex.
J Biol Chem. 1991;266:1367213678.
5. Tamura M, Lam T, Inagami T. Isolation and characterization of a specific endogenous Na+,K+-ATPase inhibitor from bovine adrenal. Biochemistry. 1988;27:42444253.[Medline] [Order article via Infotrieve]
6. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994;135:794797.[Abstract]
7. Laredo J, Shah JR,. Lu Z-R, Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension. 1997;29(pt 2):401407.
8.
Hajnoczky G, Csordas G, Hunyady L, Kalapos MP, Balla
T, Enyedi P, Spat A. Angiotensin II inhibits
Na+/K+ pump in rat adrenal
glomerulosa cells: possible contribution to stimulation of
aldosterone production. Endocrinology. 1992;130:16371644.
9. Laredo J, Hamilton BP, Hamlyn JM. Secretion of endogenous ouabain from bovine adrenocortical cells: role of the zona glomerulosa and zona fasciculata. Biochem Biophys Res Commun. 1995;212:487493.[Medline] [Order article via Infotrieve]
10.
Shah JR, Laredo J, Hamilton BP, Hamlyn JM. Different
signaling pathways mediate stimulated secretion of
endogenous ouabain and aldosterone from bovine
adrenocortical cells. Hypertension. 1998;31:463468.
11. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, DuCharme D. Development of an immunoassay for endogenous digitalis-like factor. Hypertension. 1991;7:936943.
12. Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS. Ouabain is secreted by the adrenal gland in awake dogs. Am J Physiol;. 1993;264:E413E419.
13. Antonipillai I, Schick K, Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab. 1996;81:23352337.[Abstract]
14.
Cushman P. Inhibition of aldosterone
secretion by ouabain in dog adrenal cortical tissue.
Endocrinology. 1969;84:808813.
15.
Elliot ME, Hadjokas NE, Goodfriend TE. Effects of
ouabain and potassium on protein synthesis and
angiotensin-stimulated aldosterone synthesis in
bovine adrenal glomerulosa cells. Endocrinology. 1986;118:14691475.
16. Kenyon CJ, Shepherd RM, Fraser R, Pediani JD, Elder HY. The role of potassium and other ions in the control of aldosterone synthesis. Endocr Res. 1991;17:225236.[Medline] [Order article via Infotrieve]
17. Nakajima S, Suzuki H, Saito I, Saruta T. Effects of atrial natriuretic peptide, dopamine and ouabain on aldosterone synthesis. Acta Endocrinolog. 1987;115:5762.
18. Szalay KS. The effect of ouabain on aldosterone production in the rat. Acta Endocrinolog. 1971;68:477484.
19. Manunta P, Rogowski AC, Hamilton BP, Hamlyn JM. Ouabain-induced hypertension in the rat: relationships among circulating and tissue ouabain and blood pressure. J Hypertens. 1994;12:549560.[Medline] [Order article via Infotrieve]
20. Juhaszova M, Blaustein MP. Na+ pump low and high ouabain affinity alpha subunit isoforms are differently distributed in cells. Proc Natl Acad Sci U S A. 1997;94:18001805.
21. Meuli C, Muller J. Characterization of rat capsular adrenal (zona glomerulosa) Na,K-ATPase activity. J Steroid Biochem Mol Biol. 1982;16:129132.
22. Douglas J, Saltman S, Williams C, Bartley P, Kondo T, Catt K. An examination of possible mechanisms of angiotensin II-stimulated steroidogenesis. Endocr Res. 1978;5:173188.
23.
van der Bent V, Demole C, Johnson EI, Rossier MF,
Python CP, Vallotton MB, Capponi AM. Angiotensin-II
induces changes in the cytosolic sodium concentration in bovine adrenal
glomerulosa cells: involvement in the activation of
aldosterone biosynthesis. Endocrinology. 1993;133:12131220.
24. Szalay KS. Ouabain: a local, paracrine, aldosterone synthesis regulating hormone? Life Sci. 1993;52:17771780.[Medline] [Order article via Infotrieve]
25. Szalay KS, Beck M, Toth M, de Chatel R. Interactions between ouabain, atrial natriuretic peptide, angiotensin II and potassium: effects on rat zona glomerulosa aldosterone production. Life Sci. 1998;62:18451852.[Medline] [Order article via Infotrieve]
26.
Tamura M, Piston DW, Tani M, Naruse M, Landon EJ,
Inagami T. Ouabain increases aldosterone release from
bovine adrenal glomerulosa cells: role of renin-angiotensin
system. Am J Physiol. 1996;270:E27E35.
27. Rossi GP, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A, Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens. 1995;13:11811191.[Medline] [Order article via Infotrieve]
28. Goto A, Yamada K. An approach to the development of novel antihypertensive drugs: potential role of sodium pump inhibitors. Trends Pharmacol Sci. 1998;19:201204.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Shibata, R. W. Powers, A. Rajakumar, F. von Versen-Hoynck, M. J. Gallaher, D. L. Lykins, J. M. Roberts, and C. A. Hubel Angiotensin II decreases system A amino acid transporter activity in human placental villous fragments through AT1 receptor activation Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1009 - E1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M.A.M. Qazzaz, Z. Cao, D. D. Bolanowski, B. J. Clark, and R. Valdes Jr De Novo Biosynthesis and Radiolabeling of Mammalian Digitalis-Like Factors Clin. Chem., March 1, 2004; 50(3): 612 - 620. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. El-Masri, B. J. Clark, H. M. Qazzaz, and R. Valdes Jr Human Adrenal Cells in Culture Produce Both Ouabain-like and Dihydroouabain-like Factors Clin. Chem., October 1, 2002; 48(10): 1720 - 1730. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Dmitrieva and P. A. Doris Cardiotonic Steroids: Potential Endogenous Sodium Pump Ligands with Diverse Function Experimental Biology and Medicine, September 1, 2002; 227(8): 561 - 569. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hou and N. A. Delamere Influence of ANG II on cytoplasmic sodium in cultured rabbit nonpigmented ciliary epithelium Am J Physiol Cell Physiol, August 1, 2002; 283(2): C552 - C559. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Wang and F. H.H. Leenen Brain Sodium Channels Mediate Increases in Brain "Ouabain" and Blood Pressure in Dahl S Rats Hypertension, July 1, 2002; 40(1): 96 - 100. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |